EUCTR2009-010672-16-IT进行中（未招募）不适用
PHASE II STUDY OF SUNITINIB IN METASTATIC RENAL CANCER WITH NON-CLEAR CELL HISTOLOGY - ONC-2008-004
ISTITUTO CLINICO HUMANITAS0 个研究点开始时间: 2009年11月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically proven diagnosis of NCCRC (papillary or cromophobe), confirmed by a central review of an expert pathologist. No previous treatment. Age superior to 18 years. ECOG Performance Status 0-2. Life expectancy of at least 12 weeks. Measurable lesions according to RECIST criteria. Adequate cardiac, hepatic, renal, and bone marrow function. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior treatment with an antiangiogenetic compound. Symptomatic and/or unstable pre-existing brain metastases. Uncontrolled hypertension. Severe or uncontrolled cardiovascular diseases (congestive heart failure, myocardial infarction) within 6 months of study. Active uncontrolled infections. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
研究者
相似试验
进行中（未招募）
1 期
Sunitinib rechallenge in metastatic kidney cancerMetastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.MedDRA version: 14.1Level: LLTClassification code 10009251Term: Clear cell carcinoma of the kidneySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000473-23-ITGIOM - Gruppo Italiano Oncologia Nefrologica
进行中（未招募）
不适用
Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel. - PROSUTEUCTR2007-003048-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
1 期
A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer - SUN-CYCL (Sunitinib + Cyclophosphamide in RCC)Metastatic Renal Cell CarcinomaMedDRA version: 9.1 Level: LLT Classification code 10050513 Term: Metastatic renal cell carcinomaEUCTR2008-008676-13-GBThe Royal Marsden NHS Foundation Trust19
进行中（未招募）
1 期
Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.germ cell tumorEUCTR2007-004981-42-SKarodny onkologicky ustav28
进行中（未招募）
1 期
Retreatment with sunitinib in patients with metastatic (spread) kidney cancer.EUCTR2012-002891-15-NLVU University Medical Center45